Recent Advances in Diagnostic and Treatment Strategies in Malignant Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 February 2023) | Viewed by 11302
Special Issue Editor
Special Issue Information
Dear Colleagues,
In the last decade, tremendous progress was achieved in the understanding of the biology of malignant lymphoma. In particular, advances in pathology, genetics, molecular biology and bioinformatics have led to new insights in the way malignant lymphoma arises and evolves. Now this knowledge is transforming the diagnostic and therapeutic landscape of malignant lymphoma in an unprecedented way. In particular, new diagnostic classification systems that are based on genetic and molecular profiling will lead to very tailored, personalized and ultimately patient-specific treatment protocols. Within these protocols, combinations of various approaches, such as targeted therapy, immune therapy, gene therapy and future treatments, have the potential not only to eradicate the disease but also to achieve long-term remissions, or even a cure, for an increasing number of patients. This Special Issue will address in detail the latest exciting developments in the field.
Prof. Dr. Mathias Witzens-Harig
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lymphoma
- pathology
- genetics
- molecular biology
- bioinformatics
- targeted therapy
- immunotherapy
- gene therapy
- personalized medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.